<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Detection Rate of Recurrent Medullary Thyroid Carcinoma Using Fluorine-18 Dihydroxyphenylalanine Positron Emission Tomography" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/detection-rate-of-recurrent-medullary-thyroid-carcinoma-using-fluorine-18-dihydroxyphenylalanine-pos/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/detection-rate-of-recurrent-medullary-thyroid-carcinoma-using-fluorine-18-dihydroxyphenylalanine-pos/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2012-09-30T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Detection Rate of Recurrent Medullary Thyroid Carcinoma Using Fluorine-18 Dihydroxyphenylalanine Positron Emission Tomography" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T02:43:55+00:00","datePublished":"2012-09-30T17:00:00+00:00","description":"Rationale and Objectives","headline":"Detection Rate of Recurrent Medullary Thyroid Carcinoma Using Fluorine-18 Dihydroxyphenylalanine Positron Emission Tomography","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/detection-rate-of-recurrent-medullary-thyroid-carcinoma-using-fluorine-18-dihydroxyphenylalanine-pos/"},"url":"https://clinicaltree.github.io/posts/detection-rate-of-recurrent-medullary-thyroid-carcinoma-using-fluorine-18-dihydroxyphenylalanine-pos/"}</script><title>Detection Rate of Recurrent Medullary Thyroid Carcinoma Using Fluorine-18 Dihydroxyphenylalanine Positron Emission Tomography | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Detection Rate of Recurrent Medullary Thyroid Carcinoma Using Fluorine-18 Dihydroxyphenylalanine Positron Emission Tomography</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Detection Rate of Recurrent Medullary Thyroid Carcinoma Using Fluorine-18 Dihydroxyphenylalanine Positron Emission Tomography</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1349024400" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Sep 30, 2012 </em> </span> <span> Updated <em class="" data-ts="1681094635" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Giorgio Treglia MD</a> </em>, <em> <a href="">Fabrizio Cocciolillo MD</a> </em>, <em> <a href="">Francesco Di Nardo MD</a> </em>, <em> <a href="">Andrea Poscia MD</a> </em>, <em> <a href="">Chiara de Waure MD</a> </em>, <em> <a href="">Alessro Giordano MD</a> </em>, <em> <a href="">Vittoria Rufini MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2834 words"> <em>15 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The aim of this study was to perform a meta-analysis of published data about the diagnostic performance of 18 F-dihydroxyphenylalanine (DOPA) positron emission tomography (PET) or PET/computed tomography (CT) in detecting recurrent medullary thyroid carcinoma (MTC).</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>A comprehensive literature search of studies indexed in the PubMed/MEDLINE, Scopus, and Embase databases through January 2012 and regarding 18 F-DOPA PET or PET/CT in patients with suspected recurrent MTC was carried out. Pooled detection rates (DR) in per patient and per lesion analyses were calculated. A subanalysis considering serum levels of calcitonin and carcinoembryonic antigen, device used, and carbidopa pretreatment was also performed.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Eight studies including 146 patients with suspected recurrent MTC were included. The DRs of 18 F-DOPA PET and PET/CT in per patient and per lesion analyses were 66% and 71%, respectively. DRs significantly increased in patients with serum calcitonin ≥1000 ng/L (86%) and calcitonin doubling times &lt;24 months (86%).</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Fluorine-18-DOPA PET and PET/CT may be useful functional imaging methods in detecting recurrent MTC. The DR of recurrent MTC using these imaging methods increases in patients with higher calcitonin levels and lower calcitonin doubling times.</p><p>Medullary thyroid carcinoma (MTC) is an uncommon neuroendocrine tumor that originates from parafollicular C cells and accounts for approximately 5% of thyroid tumors, occurring in either sporadic (75% of cases) or familial (25% of cases) forms. This tumor is frequently aggressive; the most frequent sites of metastatic disease are the cervical and thoracic lymph nodes, lungs, liver, and bone. The mainstay of treatment for MTC is surgical resection .</p><p>Serum calcitonin represents the most sensitive and accurate tumor marker in the postoperative management and surveillance of MTC. In about one third of patients with MTC lesions, carcinoembryonic antigen (CEA) levels may also be increased, and this finding has prognostic significance, because increased CEA levels are characteristic of advanced forms when the tumor tends toward dedifferentiation. Serum calcitonin and CEA doubling times are efficient tools for assessing tumor progression and are useful prognostic factors in patients with MTC . In the presence of a significant increase of serum calcitonin or CEA levels after surgery, the search for recurrent or metastatic disease by imaging is indicated . These imaging modalities include neck ultrasound, computed tomography (CT), magnetic resonance imaging, positron emission tomography (PET) with different radiopharmaceuticals, and bone scintigraphy .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="search-strategy"><span class="mr-2">Search Strategy</span><a href="#search-strategy" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="study-selection"><span class="mr-2">Study Selection</span><a href="#study-selection" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="data-abstraction"><span class="mr-2">Data Abstraction</span><a href="#data-abstraction" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="quality-assessment"><span class="mr-2">Quality Assessment</span><a href="#quality-assessment" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Questions Used to Assess the Risk for Bias and Concerns Regarding Applicability for Studies Included in This Meta-analysis</p><p>Domain 1 (patient selection)</p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p></ul></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></ul></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Domain 2 (index test)</p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p></ul></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></ul></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Domain 3 (reference standard)</p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p></ul></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></ul></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Domain 4 (flow and timing)</p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><ul><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><li><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p></ul></ul><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analyses"><span class="mr-2">Statistical Analyses</span><a href="#statistical-analyses" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="literature-search"><span class="mr-2">Literature Search</span><a href="#literature-search" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DetectionRateofRecurrentMedullaryThyroidCarcinomaUsingFluorine18DihydroxyphenylalaninePositronEmissionTomography/0_1s20S1076633212003054.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DetectionRateofRecurrentMedullaryThyroidCarcinomaUsingFluorine18DihydroxyphenylalaninePositronEmissionTomography/0_1s20S1076633212003054.jpg" alt="Figure 1, Flowchart of the search for eligible studies on the diagnostic performance of 18 F dihydroxyphenylalanine positron emission tomography (PET) and PET/computed tomography in patients with suspected recurrent medullary thyroid carcinoma." class="lazyload" data-proofer-ignore></a></p><p>Table 2</p><p>Basic Study and Patient Characteristics</p><p>Authors Journal Year Country Patients with MTC Undergoing 18 F-DOPA PET or PET/CT Mean Age (y) Men Treglia et al <em>Eur J Nucl Med Mol Imaging</em> 2012 Italy 18 53 33% Kauhanen et al <em>J Nucl Med</em> 2011 Finland 19 52 53% Luster et al <em>Thyroid</em> 2010 Germany 26 (28 scans) 48 46% Marzola et al <em>Eur J Surg Oncol</em> 2010 Italy 18 51 44% Beheshti et al <em>Eur Radiol</em> 2009 Austria 19 ∗ 59 38% Koopmans et al <em>J Nucl Med</em> 2008 Netherlands 21 56 48% Beuthien-Baumann et al <em>Eur J Nucl Med Mol Imaging</em> 2007 Germany 15 56 53% Hoegerle et al <em>Eur J Nucl Med</em> 2001 Austria 10 ∗ 57 55%</p><p>CT, computed tomography; DOPA, dihydroxyphenylalanine; MTC, medullary thyroid carcinoma; PET, positron emission tomography.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 3</p><p>Technical Aspects of the Studies Using 18 F-DOPA PET and PET/CT for Detecting Recurrent or Residual Medullary Thyroid Carcinoma</p><p>Authors Study Design Tracers Used Device Mean 18 F-DOPA Injected Activity Time between Injection and Image Acquisition (min) Acquisition Protocol for PET Image Analysis Reference Standard Treglia et al Retrospective multicenter 18 F-DOPA, 18 F-FDG, 68 Ga-SMS PET/CT 4 MBq/kg 60 Static acquisition (3 min per bed position), no carbidopa premedication Qualitative Histology and/or clinical/imaging follow-up Kauhanen et al Prospective multicenter 18 F-DOPA, 18 F-FDG PET/CT 243 MBq 60 Static acquisition (3 min per bed position) carbidopa premedication Qualitative and semiquantitative Histology and/or clinical/imaging follow-up Luster et al Retrospective single center 18 F-DOPA PET/CT 298 MBq 60 Static acquisition (4 min per bed position), carbidopa premedication Qualitative and semiquantitative Histology and/or clinical/imaging follow-up Marzola et al Multicenter 18 F-DOPA, 18 F-FDG PET/CT 2.2 MBq/kg 60 Static acquisition (3 min per bed position), no carbidopa premedication Qualitative and semiquantitative Histology Beheshti et al Prospective single center 18 F-DOPA, 18 F-FDG PET/CT 4 MBq/Kg 30 Static acquisition (4 min per bed position), no carbidopa premedication Qualitative and semiquantitative Histology and/or clinical/imaging follow-up Koopmans et al Prospective single center 18 F-DOPA, 18 F-FDG PET 180 MBq 60 Static acquisition (5 min per bed position), carbidopa premedication Qualitative Histology and/or clinical/imaging follow-up Beuthien-Baumann et al Retrospective single center 18 F-DOPA, 18 F-FDG, 18 F-OMFD PET 4.8 MBq/Kg 45 Static acquisition, carbidopa premedication Qualitative Histology and/or clinical/imaging follow-up Hoegerle et al Prospective single center 18 F-DOPA, 18 F-FDG PET 220 MBq 90 Static acquisition, no carbidopa premedication Qualitative Histology and/or clinical/imaging follow-up</p><p>CT, computed tomography; DOPA, dihydroxyphenylalanine; FDG, fluorodeoxyglucose; OMFD, methylfluorodihydroxyphenylalanine; PET, positron emission tomography; SMS, somatostatin analogue.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="quality-assessment-1"><span class="mr-2">Quality Assessment</span><a href="#quality-assessment-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 4</p><p>Results of the Quality Assessment According to the QUADAS-2 Tool: Evaluation of the Risk for Bias and Applicability Concerns</p><p>Study Risk for Bias Applicability Concerns Patient Selection Index Test Reference Standard Flow and Timing Patient Selection Index Test Reference Standard Treglia et al Low Low Unclear High Low Low Low Kauhanen et al Low Low Unclear High Low Low Low Luster et al Low Low High High Low Low Low Marzola et al Low Low Low Low Low Low Low Beheshti et al Low Low Unclear High Low Low Low Koopmans et al Low Low Unclear High Low Low Low Beuthien-Baumann et al High Unclear High High Low Low High Hoegerle et al Unclear Low Low High Low Low Low</p><p>QUADAS-2, Revised Quality Assessment of Diagnostic Accuracy Studies.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="diagnostic-performance"><span class="mr-2">Diagnostic Performance</span><a href="#diagnostic-performance" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 5</p><p>Detection Rates of 18 F-DOPA PET and PET/CT in the Included Studies</p><p>Study Detection Rate Patient-based Analysis ( <em>n</em> = 139) Lesion-based Analysis ( <em>n</em> = 124) Calcitonin ≥ 1000 ng/L † ( <em>n</em> = 45) Calcitonin &lt; 150 ng/L † ( <em>n</em> = 28) Calcitonin ≥ 150 ng/L † ( <em>n</em> = 93) CEA ≤ 5 ng/mL † ( <em>n</em> = 29) CEA &gt; 5 ng/mL † ( <em>n</em> = 69) Treglia et al 13/18 72% 61/72 85% 5/7 100% 2/2 100% 11/16 69% 3/4 75% 10/14 71% Kauhanen et al 11/19 58% 61/118 52% 5/6 83% 0/5 0% 11/14 79% 3/8 37% 8/11 73% Luster et al 14/19 ‡ 74% 35/51 68% 8/8 100% 3/8 37% 11/11 100% - - - - Marzola et al 15/18 83% 84/111 76% - - - - - - - - - - Beheshti et al 14/19 74% 50/53 ∗ 94% ∗ 5/6 83% 1/2 50% 13/17 76% 4/6 67% 10/13 77% Koopmans et al 13/21 62% 95/134 71% 11/12 92% 1/5 20% 12/16 75% 2/7 29% 11/14 79% Beuthien-Baumann et al 7/15 47% NC 0/1 0 2/6 33% 5/9 56% 2/4 50% 3/7 43% Hoegerle et al 5/10 50% 17/27 63% 4/5 80% 0/0 NC 5/10 50% 0/0 NC 5/10 50% Pooled results 66% 71% 86% 39% 73% 48% 64% 95% confidence interval 58%–74% 67%–75% 73%–95% 20%–61% 63%–82% 29%–67% 52%–74% Heterogeneity (I 2 test) 15% 87% 0% 16% 46% 0% 51%</p><p>CEA, carcinoembryonic antigen; CT, computed tomography; DOPA, dihydroxyphenylalanine; NC, not calculable; PET, positron emission tomography.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 6</p><p>Detection Rates of 18 F-DOPA PET and PET/CT in the Included Studies</p><p>Study Detection Rate CTDT &gt; 24 Months ∗ ( <em>n</em> = 42) CTDT &lt; 24 Months ∗ ( <em>n</em> = 35) CTDT &gt; 12 Months ∗ ( <em>n</em> = 50) CTDT &lt; 12 Months ∗ ( <em>n</em> = 27) Only PET/CT ∗ ( <em>n</em> = 93) Carbidopa Premedication ∗ ( <em>n</em> = 74) No Carbidopa Premedication ∗ ( <em>n</em> = 65) Treglia et al 4/9 44% 9/9 100% 6/11 55% 7/7 100% 13/18 72% - - 13/18 72% Kauhanen et al 6/11 55% 5/8 62% 9/14 64% 2/5 40% 11/19 58% 11/19 58% - - Luster et al - - - - - - - - 14/19 † 74% 14/19 † 74% - - Marzola et al - - - - - - - - 15/18 83s% - - 15/18 83% Beheshti et al 2/6 33% 12/13 92% 3/7 43% 11/12 92% 14/19 74% - - 14/19 74% Koopmans et al 9/16 56% 4/5 80% 10/18 56% 3/3 100% - - 13/21 62% - - Beuthien-Baumann et al - - - - - - - - - - 7/15 47% - - Hoegerle et al - - - - - - - - - - - - 5/10 50% Pooled results 50% 86% 56% 85% 72% 61% 72% 95% confidence interval 34%–66% 70%–95% 41%–70% 66%–96% 62%–81% 49%–72% 60%–83% Heterogeneity (I 2 test) 0% 50% 0% 67% 0% 0% 13%</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DetectionRateofRecurrentMedullaryThyroidCarcinomaUsingFluorine18DihydroxyphenylalaninePositronEmissionTomography/1_1s20S1076633212003054.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DetectionRateofRecurrentMedullaryThyroidCarcinomaUsingFluorine18DihydroxyphenylalaninePositronEmissionTomography/1_1s20S1076633212003054.jpg" alt="Figure 2, Plot of individual studies and pooled detection rate of 18 F dihydroxyphenylalanine positron emission tomography and positron emission tomography/computed tomography in per patient analysis in suspected recurrent medullary thyroid carcinoma, including 95% confidence intervals (CIs). The size of each square indicates the weight of the corresponding study." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DetectionRateofRecurrentMedullaryThyroidCarcinomaUsingFluorine18DihydroxyphenylalaninePositronEmissionTomography/2_1s20S1076633212003054.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/DetectionRateofRecurrentMedullaryThyroidCarcinomaUsingFluorine18DihydroxyphenylalaninePositronEmissionTomography/2_1s20S1076633212003054.jpg" alt="Figure 3, Plot of individual studies and pooled detection rate of 18 F dihydroxyphenylalanine positron emission tomography and positron emission tomography/computed tomography in per lesion analysis in suspected recurrent medullary thyroid carcinoma, including 95% confidence intervals (CIs). The size of each square indicates the weight of the corresponding study." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="conclusions-1"><span class="mr-2">Conclusions</span><a href="#conclusions-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Pitt S.C., Moley J.F.: Medullary, anaplastic, and metastatic cancers of the thyroid. Semin Oncol 2010; 37: pp. 567-579.</p><li><p>2. American Thyroid Association Guidelines Task Force, Kloos R.T., Eng C., Evans D.B., et. al.: Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19: pp. 565-612.</p><li><p>3. Rufini V., Treglia G., Perotti G., et. al.: Role of PET in medullary thyroid carcinoma. Minerva Endocrinol 2008; 33: pp. 67-73.</p><li><p>4. Rufini V., Castaldi P., Treglia G., et. al.: Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 2008; 62: pp. 139-146.</p><li><p>5. Jager P.L., Chirakal R., Marriott C.J., et. al.: 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008; 49: pp. 573-586.</p><li><p>6. Whiting P.F., Rutjes A.W., Westwood M.E., et. al.: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: pp. 529-536.</p><li><p>7. Zamora J., Abraira V., Muriel A., et. al.: Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: pp. 31.</p><li><p>8. Kauhanen S., Seppänen M., Ovaska J., et. al.: The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer 2009; 16: pp. 255-265.</p><li><p>9. Treglia G., Castaldi P., Villani M.F., et. al.: Comparison of (18)F-DOPA, (18)F-FDG and (68)Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2012; 39: pp. 569-580.</p><li><p>10. Kauhanen S., Schalin-Jäntti C., Seppänen M., et. al.: Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med 2011; 52: pp. 1855-1863.</p><li><p>11. Luster M., Karges W., Zeich K., et. al.: Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 2010; 20: pp. 527-533.</p><li><p>12. Marzola M.C., Pelizzo M.R., Ferdeghini M., et. al.: Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol 2010; 36: pp. 414-421.</p><li><p>13. Beheshti M., Pöcher S., Vali R., et. al.: The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol 2009; 19: pp. 1425-1434.</p><li><p>14. Koopmans K.P., de Groot J.W., Plukker J.T., et. al.: 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 2008; 49: pp. 524-531.</p><li><p>15. Beuthien-Baumann B., Strumpf A., Zessin J., et. al.: Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007; 34: pp. 1604-1609.</p><li><p>16. Hoegerle S., Altehoefer C., Ghanem N., et. al.: 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001; 28: pp. 64-71.</p><li><p>17. Treglia G., Castaldi P., Rindi G., et. al.: Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012; Feb 20, Epub ahead of print</p><li><p>18. Conry B.G., Papathanasiou N.D., Prakash V., et. al.: Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010; 37: pp. 49-57.</p><li><p>19. Pałyga I., Kowalska A., Gąsior-Perczak D., et. al.: The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (68Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endokrynol Pol 2010; 61: pp. 507-511.</p><li><p>20. Treglia G., Villani M.F., Giordano A., et. al.: Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 2012; Apr 17, Epub ahead of print</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-19/'>Volume 19</a>, <a href='/categories/issue-10/'>Issue 10</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Detection%20Rate%20of%20Recurrent%20Medullary%20Thyroid%20Carcinoma%20Using%20Fluorine-18%20Dihydroxyphenylalanine%20Positron%20Emission%20Tomography%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fdetection-rate-of-recurrent-medullary-thyroid-carcinoma-using-fluorine-18-dihydroxyphenylalanine-pos%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Detection%20Rate%20of%20Recurrent%20Medullary%20Thyroid%20Carcinoma%20Using%20Fluorine-18%20Dihydroxyphenylalanine%20Positron%20Emission%20Tomography%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fdetection-rate-of-recurrent-medullary-thyroid-carcinoma-using-fluorine-18-dihydroxyphenylalanine-pos%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fdetection-rate-of-recurrent-medullary-thyroid-carcinoma-using-fluorine-18-dihydroxyphenylalanine-pos%2F&text=Detection%20Rate%20of%20Recurrent%20Medullary%20Thyroid%20Carcinoma%20Using%20Fluorine-18%20Dihydroxyphenylalanine%20Positron%20Emission%20Tomography%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/automated-texture-based-quantification-of-centrilobular-nodularity-and-centrilobular-emphysema-in-ch/"><div class="card-body"> <em class="small" data-ts="1349024400" data-df="ll" > Sep 30, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Automated Texture-based Quantification of Centrilobular Nodularity and Centrilobular Emphysema in Chest CT Images</h3><div class="text-muted small"><p> Rationale and Objectives Characterization of smoking-related lung disease typically consists of visual assessment of chest computed tomographic (CT) images for the presence and extent of emphysema...</p></div></div></a></div><div class="card"> <a href="/posts/characterization-and-normal-measurements-of-the-left-ventricular-outflow-tract-by-ecg-gated-cardiac/"><div class="card-body"> <em class="small" data-ts="1349024400" data-df="ll" > Sep 30, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Characterization and Normal Measurements of the Left Ventricular Outflow Tract by ECG-gated Cardiac CT</h3><div class="text-muted small"><p> Rationale and Objectives Studies suggest that electrocardiographically gated coronary computed tomographic angiography provides a clear definition of the left ventricular outflow tract (LVOT), and...</p></div></div></a></div><div class="card"> <a href="/posts/comparison-of-the-sensitivity-of-a-pre-mri-questionnaire-and-point-of-care-egfr-testing-for-detectio/"><div class="card-body"> <em class="small" data-ts="1349024400" data-df="ll" > Sep 30, 2012 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Comparison of the Sensitivity of a Pre-MRI Questionnaire and Point of Care eGFR Testing for Detection of Impaired Renal Function</h3><div class="text-muted small"><p> Rationale and Objectives The Food and Drug Administration recommends renal function estimation using laboratory testing for patients at risk for chronically reduced kidney function before the admi...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/delineation-of-optic-radiation-and-stria-of-gennari-on-high-resolution-phase-difference-enhanced-ima/" class="btn btn-outline-primary" prompt="Older"><p>Delineation of Optic Radiation and Stria of Gennari on High-resolution Phase Difference Enhanced Imaging</p></a> <a href="/posts/dual-energy-computed-tomography-dect-in-renal-masses/" class="btn btn-outline-primary" prompt="Newer"><p>Dual-energy Computed Tomography (DECT) in Renal Masses</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
